Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

HH 2710

Next Previous
Drug Profile

HH 2710

Alternative Names: HH-2710

Latest Information Update: 18 Apr 2023

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator HaiHe Biopharma
  • Class Antineoplastics; Immunotherapies
  • Mechanism of Action Mitogen-activated protein kinase 1 inhibitors; Mitogen-activated protein kinase 3 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase I/II Solid tumours

Most Recent Events

  • 31 Mar 2023 ShangHai HaiHe Pharmaceutical terminates a first-in-human phase I/II trial in Solid tumours (Inoperable/Unresectable, Late-stage disease, Metastatic disease) in China and USA (PO), due to sponsor's business decision (NCT04198818)
  • 22 Jun 2020 Pharmacokinetics and pharmacodynamics data from preclinical trials in Solid tumours presented at 111th Annual Meeting of the American Association for Cancer Research - II (AACR-II-2020)
  • 07 Jan 2020 Phase-I/II clinical trials in Solid tumours (Inoperable/Unresectable, Late-stage disease, Metastatic disease) in USA (PO) (NCT04198818)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top